Thyrocare Technologies, owned by digital healthcare platform PharmEasy, reported a sharp 48% year-on-year rise in net profit to INR 28 crore for the third quarter of the ongoing financial year, underscoring the diagnostics firm’s improving operational efficiency and resilient demand environment.
The strong profit growth came despite a challenging macro backdrop for India’s broader healthcare and startup ecosystem. Thyrocare’s performance highlights how established diagnostics players with asset-light models and strong brand recall continue to find stability even as discretionary healthcare spending remains uneven across regions.
Revenue Growth Remains Steady
For the quarter ended December
...
